Lumon's agenda aims to eliminate trauma, not cloning

In the season finale of Severance Season 2, viewers discover more about Lumon's “grand agendum,” a term hinting at the company's ultimate objective. This revelation contradicts earlier theories about the company working on cloning humans, which actors had already dismissed as mundane. The episode reveals that a character named Gemma is not dead but is instead being held on a special Testing Floor. Mark, another central character, activates various versions of Gemma. It becomes clear that the project aims to eliminate individuals' pain and trauma, but this endeavor raises serious ethical concerns. Kier Eagan, the company's founder, is shown in a robot form congratulating Mark on progressing toward his grand mission. This mission is framed as a “cure” for pain, but it may come at the cost of stripping away what makes a person unique. The storyline suggests that Lumon's experiments could potentially erase Gemma's memories and emotions, effectively killing the person she once was. Mark interrupts this process to rescue Gemma, leaving uncertain what would happen next. As Season 3 approaches, questions remain about why Mark seems to be the only employee capable of navigating Lumon's complexities, raising possibilities about his unique connection to Gemma. The series hints at deeper themes, questioning whether the pursuit of a pain-free life is truly worth the potential loss of identity.